ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK rare-disease unit goes to Orchard

by Michael McCoy
April 15, 2018 | APPEARED IN VOLUME 96, ISSUE 16

GlaxoSmithKline will exit the rare-disease field by transferring its business to Orchard Therapeutics. In exchange, GSK will get a 19.9% stake in Orchard. The portfolio being transferred includes Strimvelis, a gene therapy approved in Europe in 2016 to treat children with a rare immunodeficiency. GSK announced plans to exit the field last year as part of a narrowing of its R&D focus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment